This page is for healthcare professionals only.
A Galapagos product may be discussed at these events.
Find the abbreviated SmPC here.
This page is not affiliated with ECCO.
This symposium was funded and organised by Galapagos.

Post-ECCO'24

 

We were proud to have been a sponsor of the 19th Congress of ECCO, which took place in Stockholm during 21-24 February 2024.

Each year, the ECCO scientific programme includes a wide range of sessions presented by some of the world's leading specialists in IBD, exploring highlights from recently published guidelines, clinical practice and important new data.

On 31 January 2024, Galapagos completed the transaction to transfer its entire Jyseleca® (filgotinib) business to Alfasigma. The transaction includes the European and UK Marketing Authorizations, and the commercial, medical affairs and development activities for Jyseleca®.

Satellite
symposium

Stay tuned to see headlines from the Galapagos-sponsored symposium at ECCO'24.
 
 
 

 

Faculty


Abstracts*

Posters and presentations will be made available as soon as they are presented at ECCO'24 (please see individual presentation times below).


Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V Loftus, Jr, Ian Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Tomasz Masior, Christine Rudolph, Laurent Peyrin-Biroulet
Session name: Guided Poster Session
Poster number: P678
Session date: Friday, February 23, 2024
Session time: 12:40 - 13:40
Session hall: Poster Exhibition, Hall A
 


Stefan Schreiber, Brian G Feagan, Séverine Vermeire, Silvio Danese, Veerle Vyncke, Margaux Faes, Alessandra Oortwijn, Laurent Peyrin-Biroulet
Session name: Guided Poster Session
Poster number: P772
Session date: Friday, February 23, 2024
Session time: 12:40 - 13:40
Session hall: Poster Exhibition, Hall A
 


Fernando Magro, Brian G Feagan, Gerhard Rogler, Laurent Peyrin-Biroulet, Yasmina Bauer, Laure Cougnaud, Alessandra Oortwijn, Matthew Randall, Christine Rudolph, Walter Reinisch
Session name: Guided Poster Session
Poster number: P225
Session date: Friday, February 23, 2024
Session time: 12:40 - 13:40
Session hall: Poster Exhibition, Hall A
 


*Filgotinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib is not approved for Crohn's disease. 
Filgotinib should only be used if no suitable treatment alternatives are available in patients 65 years of age and older, with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), or with malignancy risk factors (e.g. current malignancy or history of malignancy).

Posters and presentations will be made available as soon as they are presented at ECCO'24 (please see individual presentation times below).


Xavier Calvet, Maria Giovanna Ferrario, Vanessa Marfil Vives, Santos Armenteros, Manuel Barreiro-de Acosta
Session name: Guided Poster Session
Poster number: P368
Session date: Friday, February 23, 2024
Session time: 12:40 - 13:40
Session hall: Poster Exhibition, Hall A
 


Javier P Gisbert, Stefan Schreiber, Corey A Siegel, Fernando Magro, Anna Jus, Chiara Whichello, Christine Michaels-Igbokwe, Sebastian Heidenreich, Alessandra Oortwijn, Séverine Vermeire
Session name: Guided Poster Session
Poster number: P551
Session date: Friday, February 23, 2024
Session time: 12:40 - 13:40
Session hall: Poster Exhibition, Hall A
 


*Filgotinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib is not approved for Crohn's disease. 
Filgotinib should only be used if no suitable treatment alternatives are available in patients 65 years of age and older, with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), or with malignancy risk factors (e.g. current malignancy or history of malignancy).

News and views

Stay up to date!

I would like to receive informational and promotional communication via e-mail concerning Galapagos' products and services. 

This field is required
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.
This field is required
Regex pattern not matched.
You must maintain minimum length.
The number is too long
Value did not matched with each other.
This field is required
This field is required
Regex pattern not matched.
You must maintain minimum length.
You must maintain maximum length.
Value did not matched with each other.

Related events


See all our events

Visit our website to register for access to our full catalogue of medical education!